魅影直播

Rick joined Beacon (previously known as Findacure) as the charity鈥檚 third member of staff and first-ever Scientific Officer. His aim was to drive forward the charity鈥檚 work in drug repurposing.

Rick became CEO in 2017 and has since been involved in almost all of Beacon鈥檚 projects. He drives the organisation鈥檚 growth and strategy, co-leads two work packages in REMEDi4ALL alongside EURORDIS, and is part of the coordinating hub for LifeArc鈥檚 Translational Centres for Rare Disease. He has written articles, given talks and provided training across Europe focusing on topics as such as patient engagement in research, the repurposing of generic medicines, and rare disease policy. Rick proudly champions rare disease patient organisations, and is continually amazed by the work, knowledge, and commitment of rare disease patient group leaders.

Before Beacon, Rick secured a PhD in Evolutionary biology at Cambridge鈥檚 Museum of Zoology and spent time educating both undergraduate and school aged students.